Last 12 months
Inside the activity.
0 purchase rows · 20 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 15 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 18, 2026 Filed Feb 20, 2026 21:49 UTC |
DEC TIMOTHY CSenior Vice-President & CFO
|
GrantRestricted Stock Unit · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001194020-26-000002 · wk-form4_1771624144.xml · derivative · entry 3 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F4 · derivative.exercise_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 18, 2027. F4 · derivative.expiration_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 18, 2027. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:49 UTC |
DEC TIMOTHY CSenior Vice-President & CFO
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 17,500 | $0.00 Strike: $50.20 | $0.00 |
DisclosureSEC source: 0001194020-26-000002 · wk-form4_1771624144.xml · derivative · entry 2 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2036-02-18 F2 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 18, 2027. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:45 UTC |
GEMAYEL GEORGESDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 4,977 | $0.00 Strike: $50.20 | $0.00 |
DisclosureSEC source: 0001256088-26-000002 · wk-form4_1771623910.xml · derivative · entry 2 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,977 Underlying: Common Stock · 4,977 shares Expires 2036-02-18 F3 · derivative.exercise_date: Each option vests on February 18, 2027. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:45 UTC |
GEMAYEL GEORGESDirector
|
GrantRestricted Stock Unit · Derivative | 2,989 | $0.00 | $0.00 |
DisclosureSEC source: 0001256088-26-000002 · wk-form4_1771623910.xml · derivative · entry 1 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,989 Underlying: Common Stock · 2,989 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F2 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, which will occur on February 18, 2027. F2 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, which will occur on February 18, 2027. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:46 UTC |
Khattar Jack A.Director · President, CEO
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 341,610 | $0.00 Strike: $50.20 | $0.00 |
DisclosureSEC source: 0001539937-26-000002 · wk-form4_1771623966.xml · derivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 341,610 Underlying: Common Stock · 341,610 shares Expires 2036-02-18 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 18, 2027. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:48 UTC |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
GrantRestricted Stock Unit · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001539215-26-000002 · wk-form4_1771624105.xml · derivative · entry 3 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F4 · derivative.exercise_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 18, 2027. F4 · derivative.expiration_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 18, 2027. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:48 UTC |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 13,500 | $0.00 Strike: $50.20 | $0.00 |
DisclosureSEC source: 0001539215-26-000002 · wk-form4_1771624105.xml · derivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,500 Underlying: Common Stock · 13,500 shares Expires 2036-02-18 F2 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 18, 2027. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:44 UTC |
Barlow CarroleeDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 4,977 | $0.00 Strike: $50.20 | $0.00 |
DisclosureSEC source: 0001745316-26-000002 · wk-form4_1771623865.xml · derivative · entry 2 Barlow Carrolee · CIK 0001745316 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,977 Underlying: Common Stock · 4,977 shares Expires 2036-02-18 F3 · derivative.exercise_date: Each option vests on February 18, 2027. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:44 UTC |
Barlow CarroleeDirector
|
GrantRestricted Stock Unit · Derivative | 2,989 | $0.00 | $0.00 |
DisclosureSEC source: 0001745316-26-000002 · wk-form4_1771623865.xml · derivative · entry 1 Barlow Carrolee · CIK 0001745316 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,989 Underlying: Common Stock · 2,989 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F2 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, which will occur on February 18, 2027. F2 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, which will occur on February 18, 2027. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:43 UTC |
Sensenig BethanyDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 4,977 | $0.00 Strike: $50.20 | $0.00 |
DisclosureSEC source: 0001899935-26-000003 · wk-form4_1771623777.xml · derivative · entry 2 Sensenig Bethany · CIK 0001899935 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,977 Underlying: Common Stock · 4,977 shares Expires 2036-02-18 F3 · derivative.exercise_date: Each option vests on February 18, 2027. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:43 UTC |
Sensenig BethanyDirector
|
GrantRestricted Stock Unit · Derivative | 2,989 | $0.00 | $0.00 |
DisclosureSEC source: 0001899935-26-000003 · wk-form4_1771623777.xml · derivative · entry 1 Sensenig Bethany · CIK 0001899935 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,989 Underlying: Common Stock · 2,989 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F2 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, which will occur on February 18, 2027. F2 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, which will occur on February 18, 2027. Read SEC document |
| January 09, 2026 Filed Jan 12, 2026 16:09 UTC |
Hudson Frederick M.Director
|
Exercise / conversionDirector Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $12.98 | $0.00 |
DisclosureSEC source: 0001628280-26-001817 · wk-form4_1768252183.xml · derivative · entry 2 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 09, 2026 Filed Jan 12, 2026 16:09 UTC |
Hudson Frederick M.Director
|
Exercise / conversionCommon Stock | 15,000 | $12.98 | $194,700.00 |
DisclosureSEC source: 0001628280-26-001817 · wk-form4_1768252183.xml · nonDerivative · entry 1 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,307 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 19, 2025 Filed Dec 22, 2025 21:04 UTC |
Mottola FrankSVP, Chief Tech. Ops. Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $25.30 | $0.00 |
DisclosureSEC source: 0001628280-25-058506 · wk-form4_1766437463.xml · derivative · entry 6 Mottola Frank · CIK 0001804567 · SVP, Chief Tech. Ops. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2027-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2025. F5 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 24, 2018. Read SEC document |
| December 19, 2025 Filed Dec 22, 2025 21:04 UTC |
Mottola FrankSVP, Chief Tech. Ops. Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $39.40 | $0.00 |
DisclosureSEC source: 0001628280-25-058506 · wk-form4_1766437463.xml · derivative · entry 5 Mottola Frank · CIK 0001804567 · SVP, Chief Tech. Ops. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2028-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2025. F4 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 14, 2019 . Read SEC document |
| December 19, 2025 Filed Dec 22, 2025 21:04 UTC |
Mottola FrankSVP, Chief Tech. Ops. Officer
|
SaleCommon Stock | 15,000 | $50.47 | $757,050.00 |
DisclosureSEC source: 0001628280-25-058506 · wk-form4_1766437463.xml · nonDerivative · entry 4 Mottola Frank · CIK 0001804567 · SVP, Chief Tech. Ops. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,496 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.69. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| December 19, 2025 Filed Dec 22, 2025 21:04 UTC |
Mottola FrankSVP, Chief Tech. Ops. Officer
|
Exercise / conversionCommon Stock | 15,000 | $25.30 | $379,500.00 |
DisclosureSEC source: 0001628280-25-058506 · wk-form4_1766437463.xml · nonDerivative · entry 3 Mottola Frank · CIK 0001804567 · SVP, Chief Tech. Ops. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,496 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2025. Read SEC document |
| December 19, 2025 Filed Dec 22, 2025 21:04 UTC |
Mottola FrankSVP, Chief Tech. Ops. Officer
|
SaleCommon Stock | 5,000 | $50.22 | $251,100.00 |
DisclosureSEC source: 0001628280-25-058506 · wk-form4_1766437463.xml · nonDerivative · entry 2 Mottola Frank · CIK 0001804567 · SVP, Chief Tech. Ops. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,496 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.39. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| December 19, 2025 Filed Dec 22, 2025 21:04 UTC |
Mottola FrankSVP, Chief Tech. Ops. Officer
|
Exercise / conversionCommon Stock | 5,000 | $39.40 | $197,000.00 |
DisclosureSEC source: 0001628280-25-058506 · wk-form4_1766437463.xml · nonDerivative · entry 1 Mottola Frank · CIK 0001804567 · SVP, Chief Tech. Ops. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,496 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2025. Read SEC document |
| December 18, 2025 Filed Dec 19, 2025 21:05 UTC |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
Exercise / conversionPerformance Share Unit · Derivative | 1,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001539215-25-000008 · wk-form4_1766178329.xml · derivative · entry 3 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: On February 22, 2022, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2022. F2 · derivative.expiration_date: On February 22, 2022, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2022. Read SEC document |
| December 18, 2025 Filed Dec 19, 2025 21:05 UTC |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
SaleCommon Stock | 710 | $44.44 | $31,552.40 |
DisclosureSEC source: 0001539215-25-000008 · wk-form4_1766178329.xml · nonDerivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,508 F1 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units. Read SEC document |
| December 18, 2025 Filed Dec 19, 2025 21:05 UTC |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
Exercise / conversionCommon Stock | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001539215-25-000008 · wk-form4_1766178329.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,218 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 21, 2025 Filed Nov 24, 2025 18:16 UTC |
NEWHALL CHARLES W IIIDirector
|
Exercise / conversionDirector Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $12.98 | $0.00 |
DisclosureSEC source: 0001628280-25-053877 · wk-form4_1764026210.xml · derivative · entry 2 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 21, 2025 Filed Nov 24, 2025 18:16 UTC |
NEWHALL CHARLES W IIIDirector
|
Exercise / conversionCommon Stock | 15,000 | $12.98 | $194,700.00 |
DisclosureSEC source: 0001628280-25-053877 · wk-form4_1764026210.xml · nonDerivative · entry 1 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,644 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2025 Filed Nov 17, 2025 13:54 UTC |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
GrantPerformance Share Unit · Derivative | 1,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001539215-25-000006 · wk-form4_1763387675.xml · derivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires not disclosed F1 · derivative.exercise_date: On February 22, 2022, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2022. F1 · derivative.expiration_date: On February 22, 2022, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2022. Read SEC document |
| October 09, 2025 Filed Oct 10, 2025 16:21 UTC |
NEWHALL CHARLES W IIIDirector
|
SaleCommon Stock | 1,200 | $51.55 | $61,860.00 |
DisclosureSEC source: 0001628280-25-044797 · wk-form4_1760127657.xml · nonDerivative · entry 2 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 104,644 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted March 3, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.39 to $51.76. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| October 09, 2025 Filed Oct 10, 2025 16:21 UTC |
NEWHALL CHARLES W IIIDirector
|
SaleCommon Stock | 23,800 | $50.73 | $1,207,374.00 |
DisclosureSEC source: 0001628280-25-044797 · wk-form4_1760127657.xml · nonDerivative · entry 1 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,844 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted March 3, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.12 to $51.08. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| October 09, 2025 Filed Oct 10, 2025 21:33 UTC |
Khattar Jack A.Director · President, CEO
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 81,250 | $0.00 Strike: $25.30 | $0.00 |
DisclosureSEC source: 0001628280-25-044830 · wk-form4_1760132000.xml · derivative · entry 5 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 81,250 shares Expires 2027-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vests in four equal installments beginning on February 24, 2018 Read SEC document |
| October 09, 2025 Filed Oct 10, 2025 21:33 UTC |
Khattar Jack A.Director · President, CEO
|
SaleCommon Stock | 1,529 | $51.46 | $78,682.34 |
DisclosureSEC source: 0001628280-25-044830 · wk-form4_1760132000.xml · nonDerivative · entry 3 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,206,578 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.14 to $51.76. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| October 09, 2025 Filed Oct 10, 2025 21:33 UTC |
Khattar Jack A.Director · President, CEO
|
SaleCommon Stock | 58,371 | $50.55 | $2,950,654.05 |
DisclosureSEC source: 0001628280-25-044830 · wk-form4_1760132000.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,208,107 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.11 to $51.09. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| October 09, 2025 Filed Oct 10, 2025 21:33 UTC |
Khattar Jack A.Director · President, CEO
|
Exercise / conversionCommon Stock | 81,250 | $25.30 | $2,055,625.00 |
DisclosureSEC source: 0001628280-25-044830 · wk-form4_1760132000.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,266,478 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted November 14, 2024. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 20:19 UTC |
Khattar Jack A.Director · President, CEO
|
Exercise / conversionPerformance Share Units · Derivative | 19,320 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001539937-25-000030 · wk-form4_1759522783.xml · derivative · entry 7 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,320 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. F5 · derivative.expiration_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 20:19 UTC |
Khattar Jack A.Director · President, CEO
|
Exercise / conversionPerformance Share Unit · Derivative | 20,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001539937-25-000030 · wk-form4_1759522783.xml · derivative · entry 6 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On February 19, 2021, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on April 30, 2021. F4 · derivative.expiration_date: On February 19, 2021, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on April 30, 2021. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 20:19 UTC |
Khattar Jack A.Director · President, CEO
|
Tax withholdingCommon Stock | 7,529 | $46.21 | $347,915.09 |
DisclosureSEC source: 0001539937-25-000030 · wk-form4_1759522783.xml · nonDerivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,185,228 F2 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 20:19 UTC |
Khattar Jack A.Director · President, CEO
|
Exercise / conversionCommon Stock | 19,320 | $0.00 | $0.00 |
DisclosureSEC source: 0001539937-25-000030 · wk-form4_1759522783.xml · nonDerivative · entry 3 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,192,757 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 22, 2024. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 20:19 UTC |
Khattar Jack A.Director · President, CEO
|
Tax withholdingCommon Stock | 7,796 | $46.21 | $360,253.16 |
DisclosureSEC source: 0001539937-25-000030 · wk-form4_1759522783.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,173,437 F2 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 20:19 UTC |
Khattar Jack A.Director · President, CEO
|
Exercise / conversionCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001539937-25-000030 · wk-form4_1759522783.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,181,233 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 19, 2021. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 20:18 UTC |
Khattar Jack A.Director · President, CEO
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 2,267 | $0.00 Strike: $25.30 | $0.00 |
DisclosureSEC source: 0001539937-25-000028 · wk-form4_1759522711.xml · derivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,250 Underlying: Common Stock · 2,267 shares Expires 2027-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests in four equal installments beginning on February 24, 2018 Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 20:18 UTC |
Khattar Jack A.Director · President, CEO
|
SaleCommon Stock | 1,904 | $48.06 | $91,506.24 |
DisclosureSEC source: 0001539937-25-000028 · wk-form4_1759522711.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,161,233 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.00 to $48.08. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 20:18 UTC |
Khattar Jack A.Director · President, CEO
|
Exercise / conversionCommon Stock | 2,267 | $25.30 | $57,355.10 |
DisclosureSEC source: 0001539937-25-000028 · wk-form4_1759522711.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,163,137 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted November 14, 2024. Read SEC document |
| October 01, 2025 Filed Oct 2, 2025 20:02 UTC |
Khattar Jack A.Director · President, CEO
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 53,785 | $0.00 Strike: $25.30 | $0.00 |
DisclosureSEC source: 0001539937-25-000026 · wk-form4_1759435359.xml · derivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,517 Underlying: Common Stock · 53,785 shares Expires 2027-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests in four equal installments beginning on February 24, 2018 Read SEC document |
| October 01, 2025 Filed Oct 2, 2025 20:02 UTC |
Khattar Jack A.Director · President, CEO
|
SaleCommon Stock | 40,173 | $48.07 | $1,931,116.11 |
DisclosureSEC source: 0001539937-25-000026 · wk-form4_1759435359.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,160,870 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.00 to $48.25. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| October 01, 2025 Filed Oct 2, 2025 20:02 UTC |
Khattar Jack A.Director · President, CEO
|
Exercise / conversionCommon Stock | 53,785 | $25.30 | $1,360,760.50 |
DisclosureSEC source: 0001539937-25-000026 · wk-form4_1759435359.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,201,043 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted November 14, 2024. Read SEC document |
| September 30, 2025 Filed Oct 1, 2025 20:20 UTC |
Khattar Jack A.Director · President, CEO
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 11,510 | $0.00 Strike: $25.30 | $0.00 |
DisclosureSEC source: 0001539937-25-000024 · wk-form4_1759350029.xml · derivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 137,302 Underlying: Common Stock · 11,510 shares Expires 2027-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests in four equal installments beginning on February 24, 2018 Read SEC document |
| September 30, 2025 Filed Oct 1, 2025 20:20 UTC |
Khattar Jack A.Director · President, CEO
|
SaleCommon Stock | 8,588 | $48.25 | $414,371.00 |
DisclosureSEC source: 0001539937-25-000024 · wk-form4_1759350029.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,147,258 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.00 to $48.44. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| September 30, 2025 Filed Oct 1, 2025 20:20 UTC |
Khattar Jack A.Director · President, CEO
|
Exercise / conversionCommon Stock | 11,510 | $25.30 | $291,203.00 |
DisclosureSEC source: 0001539937-25-000024 · wk-form4_1759350029.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,155,846 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted November 14, 2024. Read SEC document |
| September 29, 2025 Filed Sep 30, 2025 20:24 UTC |
Khattar Jack A.Director · President, CEO
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 13,688 | $0.00 Strike: $25.30 | $0.00 |
DisclosureSEC source: 0001539937-25-000022 · wk-form4_1759263862.xml · derivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 148,812 Underlying: Common Stock · 13,688 shares Expires 2027-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests in four equal installments beginning on February 24, 2018 Read SEC document |
| September 29, 2025 Filed Sep 30, 2025 20:24 UTC |
Khattar Jack A.Director · President, CEO
|
SaleCommon Stock | 10,235 | $48.02 | $491,484.70 |
DisclosureSEC source: 0001539937-25-000022 · wk-form4_1759263862.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,144,336 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.00 to $48.14. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| September 29, 2025 Filed Sep 30, 2025 20:24 UTC |
Khattar Jack A.Director · President, CEO
|
Exercise / conversionCommon Stock | 13,688 | $25.30 | $346,306.40 |
DisclosureSEC source: 0001539937-25-000022 · wk-form4_1759263862.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,154,571 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted November 14, 2024. Read SEC document |
| September 25, 2025 Filed Sep 26, 2025 20:17 UTC |
Rubin JonathanSVP, Chief Medical Officer
|
Exercise / conversionPerformance Share Unit · Derivative | 1,875 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001836067-25-000006 · wk-form4_1758917846.xml · derivative · entry 3 Rubin Jonathan · CIK 0001836067 · SVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. F3 · derivative.expiration_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.